3. Liu CP, Shih SC, Wang NY, et al. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect, 2016, 49(6): 934-940.
[4]
4. Lee HY, Chen CL, Wu SR, et al. Risk factors and outcome analysis of acinetobacter baumannii complex bacteremia in critical patients. Crit Care Med, 2014, 42(5): 1081-1088.
[5]
5. Huang ST, Chiang MC, Kuo SC, et al. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect, 2012, 45(5): 356-62.
[6]
6. Anunnatsiri S, Tonsawan P. Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand. Southeast Asian J Trop Med Public Health, 2011, 42(3): 693-703.
[7]
7. Routsi C, Pratikaki M, Platsouka E, et al. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection, 2010, 38(3): 173-180.
[8]
8. Shih MJ, Lee NY, Lee HC, et al. Risk factors of multidrug resistance in nosocomial bacteremia due to Acinetobacter baumannii: a case-control study. J Microbiol Immunol Infect, 2008, 41(2): 118-123.
[9]
9. Fu Q, Ye H, Liu S. Risk factors for extensive drug-resistance and mortality in geriatric inpatients with bacteremia caused by Acinetobacter baumannii. Am J Infect Control, 2015, 43(8): 857-860.
[10]
13. Kim MH, Ahn JY, Song JE, et al. The C-Reactive Protein/Albumin Ratio as an Independent Predictor of Mortality in Patients with Severe Sepsis or Septic Shock Treated with Early Goal-Directed Therapy. PLoS One, 2015, 10(7): e0132109.
[11]
10. Kim YJ, Kim SI, Hong KW, et al. Risk Factors for Mortality in Patients with Carbapenem-Resistant Acinetobacter baumannii Bacteremia: Impact of Appropriate Antimicrobial Therapy. J Korean Med Sci, 2012, 27(5): 471-475.
[12]
11. Lee YT, Kuo SC, Yang SP, et al. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin Infect Dis, 2012, 55(2): 209-215..
[13]
12. Teng SO, Yen MY, Ou TY, et al. Comparison of pneumonia- and non-pneumonia-related Acinetobacter baumannii bacteremia: Impact on empiric therapy and antibiotic resistance. J Microbiol Immunol Infect, 2015, 48(5): 525-30.
[14]
14. Chuang YC, Chang SC, Wang WK. High and increasing Oxa-51 DNA load predict mortality in Acinetobacter baumannii bacteremia: implication for pathogenesis and evaluation of therapy. PLoS One, 2010, 5(11): e14133.
[15]
15. Chuang YC, Sheng WH, Li SY, et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia. Clin Infect Dis, 2011, 52(3): 352-360.
[16]
16. Lee NY, Chang TC, Wu CJ, et al. Clinical manifestations, antimicrobial therapy, and prognostic factors of monomicrobial Acinetobacter baumannii complex bacteremia. J Infect, 2010, 61(3): 219-227.
19. Cheng A, Chuang YC, Sun HY, et al. Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study. Crit Care Med, 2015, 43(6): 1194-1204.
